Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (EPOC) ALAT-2014: Preguntas y respuestas

de, María Montes; Varela, María Victorina López; Acuña, Agustín; Schiavi, Eduardo; Rey, María Alejandra; Jardim, José Roberto; Casas, Alejandro; Tokumoto, Antonio; Duque, Carlos A. Torres; Ramírez‐Venegas, Alejandra; García, Gabriel; Stirbulov, Roberto; Camelier, Aquiles Assunção; Bergna, Miguel; Cohen, Mark E.; Guzmán, Santiago V.; Sánchez, Efraín

doi:10.1016/j.arbres.2014.11.017

Cited by 43 publications

(40 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although up-to-date guidelines for COPD treatment are available from ALAT [76][77][78] and from most national societies, the PLATINO survey showed highly variable and frequently suboptimal treatment of patients with COPD [79,80]. Only one half of smokers with COPD were counselled by a physician, and only a fourth were receiving any respiratory medication, often oral, and influenza vaccination was very scarce in several countries [79,80].…”

Section: Treatment Of Copd In Latin Americamentioning

confidence: 99%

Chronic Obstructive Pulmonary Disease in Latin America

Pérez‐Padilla

Menezes

2019

Annals of Global Health

View full text Add to dashboard Cite

Background Latin America covers a vast geographic area (larger than the United States, Canada or Western Europe) with about 600 million inhabitants distributed in at least 19 countries. The population tripled since 1950, with a massive migration from rural areas to cities. Latin America is a mixed pot of ethnicities including the European, African, Mulatto, Mestizo and Amerindian individuals, in various proportions depending on the native population prior to the arrival of Europeans and the extent of European and African migration. Unfortunately, Latin America is one of the areas in the world with the widest disparity in income within and between countries, leading to a coexistence of diseases of poverty with those seen in developed countries. Tobacco-induced diseases, diabetes, obesity and the cardiovascular disease typical of developed regions and infectious diseases and problems related to violence often overlap in the same country. Prevalence of COPD in Latin America: Data from Population-based Studies Before several population-based surveys conducted in the early 2000s, information on respiratory diseases was very scarce, beyond the compulsory data provided by the World Health Organization (WHO), mostly based on mortality statistics. The Global Burden of Disease (GBD) project (the latest conducted in 2013) [1] provided estimates

show abstract

Section: Treatment Of Copd In Latin Americamentioning

confidence: 99%

Chronic Obstructive Pulmonary Disease in Latin America

Pérez‐Padilla

Menezes

2019

Annals of Global Health

View full text Add to dashboard Cite

show abstract

“…Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2 57.14 Diagnóstico y tratamiento de la EPOC (CENETEC) 10 74.00 Chronic obstructive pulmonary disease (COPD) in over 16s: diagnosis and treatment (NICE) 16 90.99 Guía Latinoamericana de EPOC (ALAT) 17 68.01 Guías Españolas de la EPOC (GEsEPOC) 18 70.18 Management of COPD exacerbations (ERS/ATS) 19 75.15 Prevention of COPD exacerbations (ERS/ATS) 20 73.60 COPD-X Plan Australian and New Zealand Guidelines for the management of COPD 21 65.80 EPOC = enfermedad pulmonar obstructiva crónica.…”

Section: Porcentaje De Acuerdo Agree II (Dos Revisores)mentioning

confidence: 99%

“…Todo paciente con sospecha de EPOC debe completar una espirometría con prueba de broncodilatador para confirmar el diagnóstico. [1][2][3]9,10,[15][16][17][18] Evidencia 2-Recomendación C 2 Se recomienda el uso de la espirometría con broncodilatador para el diagnóstico de casos de EPOC en la población ≥ 40 años, que haya sido expuesta a factores de riesgo como tabaquismo (≥ 10 paquetes/ año), humo de leña (≥ 200 horas/año o ≥ 10 años), con síntomas respiratorios (búsqueda de casos) o sin síntomas respiratorios (tamizaje), ya sea tanto en la población abierta (global) como en la población que consulta por cualquier causa (oportunista).…”

unclassified

Guía de Práctica Clínica Mexicana para el diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica <br>GUÍA MEXICANA DE EPOC, 2020

Vázquez-García¹,

Hernández-Zenteno²,

Pérez-Padilla³

et al. 2019

NCT Neumología Y Cirugía De Tórax

View full text Add to dashboard Cite

www.medigraphic.org.mx RESUMEN. Introducción: La enfermedad pulmonar obstructiva crónica (EPOC) es una de las principales causas de muerte en México y en el mundo. Pese a que en los últimos años se ha alcanzado un gran progreso en su manejo y tratamiento, esto también ha conllevado una mayor complejidad. En México, es fundamental el desarrollo de guías de práctica clínica (GPC) que estén basadas en estándares internacionales para establecer recomendaciones a todos los niveles de atención. Objetivos: El objetivo fue desarrollar una GPC con recomendaciones clínicas desarrolladas de forma sistematizada para asistir a la toma de decisiones, tanto de médicos de todos los niveles de atención, como de pacientes, cuidadores de pacientes y todos los elaboradores de políticas públicas involucrados en el manejo de pacientes con enfermedad pulmonar obstructiva crónica. Material y métodos: Este documento fue desarrollado por parte de la Sociedad Mexicana de Neumología y Cirugía de Tórax en cumplimiento con los estándares internacionales como los descritos por el Instituto de Medicina de los Estados Unidos (IOM, por sus siglas en inglés). Se integró un Grupo de Desarrollo de la Guía (GDG) de manera interdisciplinaria, considerando la participación de neumólogos y metodólogos con experiencia en revisiones sistemáticas de la literatura y el desarrollo de GPC. De forma sistematizada, se consensuaron los alcances, las preguntas clínicas y se evaluaron otras Guías Internacionales sobre el tema. Se evaluó críticamente la calidad metodológica de esas GPC. A través del abordaje ADAPTE, se transculturizó la GPC a nuestro país y, finalmente, utilizando metodología de consenso formal de expertos, se desarrollaron las recomendaciones clínicas. Resultados: Se consensuaron 40 preguntas estructuradas clínicamente relevantes para el diagnóstico y tratamiento, así como las recomendaciones clínicas pertinentes y su texto de soporte. Las recomendaciones abarcan preguntas sobre diagnóstico y tratamiento. Conclusión: Esta GPC pretende proveer recomendaciones clínicas para el diagnóstico y manejo terapéutico de los distintos estadios de la EPOC basadas en evidencia científica, que asisten en el proceso de toma de decisiones compartidas y que esperamos contribuyan a mejorar la calidad de la atención clínica en las pacientes con EPOC. Palabras clave: Guías de Práctica Clínica, medicina basada en evidencia, enfermedad pulmonar obstructiva crónica. ABSTRACT. Introduction: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of the death in Mexico and worldwide. In recent years, great progress has been achieved in its management and treatment, which also entails greater complexity. In Mexico, the development of clinical practice guidelines (CPG) under international standards is essential to stablish recommendations at all levels of care. Objectives: This Clinical Practice Guideline provides systematically developed clinical recommendations to assist clinical decision makers involved in the management of patients with COPD. Material ...

show abstract

“…Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease; its main characteristic is progressive respiratory airways obstruction related to a chronic inflammatory response against noxious particles [Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013; Montes de Oca et al, 2015]. Worldwide, COPD has an~10% prevalence.…”

Section: Introductionmentioning

confidence: 99%

Effect of SNPs in HSP Family Genes, Variation in the mRNA and Intracellular Hsp Levels in COPD Secondary to Tobacco Smoking and Biomass-Burning Smoke

et al. 2020

Self Cite

View full text Add to dashboard Cite

Heat shock proteins (HSP) genes are a superfamily responsible for encoding highly conserved proteins that are important for antigen presentation, immune response regulation, and cellular housekeeping processes. These proteins can be increased by cellular stress related to pollution, for example, smoke from biomass burning and/or tobacco smoking. Single nucleotide polymorphisms (SNPs) in these genes could affect the levels of their proteins, as well as the susceptibility to developing lung diseases, such as chronic obstructive pulmonary disease (COPD), related to the exposure to environmental factors.Methods: The subjects included were organized into two comparison groups: 1,103 smokers (COPD patients, COPD-S = 360; smokers without COPD, SWOC = 743) and 442 never-smokers who were chronically exposed to biomass smoke (COPD patients, COPD-BS = 244; exposed without COPD, BBES = 198). Eight SNPs in three HSP genes were selected and genotyped: four in HSPA1A, two in HSPA1B, and two in HSPA1L. Sputum expectoration was induced to obtain pulmonary cells and relative quantification of mRNA expression. Subsequently, the intracellular protein levels of total Hsp27, phosphorylated Hsp27 (Hsp27p), Hsp60, and Hsp70 were measured in a sample of 148 individuals selected based on genotypes.

show abstract

Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (EPOC) ALAT-2014: Preguntas y respuestas

Cited by 43 publications

References 108 publications

Chronic Obstructive Pulmonary Disease in Latin America

Chronic Obstructive Pulmonary Disease in Latin America

Guía de Práctica Clínica Mexicana para el diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica <br>GUÍA MEXICANA DE EPOC, 2020

Effect of SNPs in HSP Family Genes, Variation in the mRNA and Intracellular Hsp Levels in COPD Secondary to Tobacco Smoking and Biomass-Burning Smoke

Contact Info

Product

Resources

About